CETYLEV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cetylev, and what generic alternatives are available?
Cetylev is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are three patents protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in CETYLEV is acetylcysteine. There are three drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the acetylcysteine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cetylev
A generic version of CETYLEV was approved as acetylcysteine by HOSPIRA on August 30th, 1994.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CETYLEV?
- What are the global sales for CETYLEV?
- What is Average Wholesale Price for CETYLEV?
Summary for CETYLEV
| International Patents: | 1 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CETYLEV |
US Patents and Regulatory Information for CETYLEV
CETYLEV is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | 9,561,204 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | 8,747,894 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | 8,747,894 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-002 | Jan 29, 2016 | DISCN | Yes | No | 9,427,421 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | 9,427,421 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Arbor Pharms Llc | CETYLEV | acetylcysteine | TABLET, EFFERVESCENT;ORAL | 207916-001 | Jan 29, 2016 | DISCN | Yes | No | 9,561,204 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CETYLEV
See the table below for patents covering CETYLEV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2662077 | COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE) | ⤷ Start Trial |
| European Patent Office | 2662077 | COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch